Preclinical studies indicated that HuMax-CD38 was effective in killing primary CD38+CD138+ patient MM cells and a range of MM/lymphoid cell lines by both ADCC and CDC [41]. This evidence concerns the gene CD38 and Miyoshi myopathy.